Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2004

View Archived Issues

Pharmacological management of infection-induced preterm labor by PDE4 inhibitors

Amylin inhibits bone resorption preclinically: potential efficacy as a treatment for osteoporosis

Merck & Co. to acquire Aton Pharma

Serono receives rights to InDex's Kappaproct

Enrollment under way in ENDEAVOR III trial

Guidant and Cordis to copromote Cypher stent in U.S.

European label change for Cialis to include 36-hour efficacy claim

Paratek and MMV partner for discovery of new antimalarial compounds

Series C financing at AlgoRx to accelerate development, expand pipeline

Attenuon and Kirin Brewery enter antibody collaboration for cancer

Uroflux completes phase II trial for BPH

AusAm receives contract grant from NIH to accelerate development of DES10

Neoprobe to meet FDA concerning RIGScan CR49 BLA

NeurogesX Series C financing to advance NGX-4010

Human Genome Sciences continues to move clinical candidates forward

Peplin Biotech reaches final stages of pre-IND activities for PEP-005

Transdermal rotigotine reported effective in early Parkinson's disease

Elidel(R) induces complete clearance in chronic hand dermatitis

Therapeutic benefits found with letrozole plus norethindrone acetate in endometriosis

Novel antihypertensive agents discovered by French researchers

New selective MAO-B inhibitors developed by Roche researchers

Novel azetidine-based DPP-IV inhibitors prepared and tested at Yamanouchi

Merck and Isis scientists present new NS5B inhibitors for HCV infection

New chemokine CCR4 antagonists in early development at Ono

New chymase inhibitors and their use in hypertension, heart failure, etc.

New prostaglandin derivatives with hypnotic activity discovered at Taisho

Mitsui Chemicals claims telomerase inhibitors for cancer and other uses

Micromet and Boehringer Ingelheim collaborate on MT-201 manufacturing

Gonal-f prefilled pen receives European approval

Orphan drug designation for CG-53135

Phase I study for aminocandin for systemic fungal infections

Phase I studies suggest a broad antifungal activity for BAL-8557